Deals
After debuting on the public markets with $256.3 million and raking in an additional $472 million, Veradermics has emerged as one of biotech’s biggest post-IPO standouts. CEO Reid Waldman credits the weight loss craze for establishing consumer-driven channels.
FEATURED STORIES
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
While merger and acquisition activity has been robust of late, frequent changes in guidance and leadership at the regulator add risk to any transaction.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Amgen will partner with Arrakis Therapeutics for an innovative collaboration to research and develop RNA degrader therapeutics.
BMS and Century Therapeutics agreed to collaborate on the research, development, and commercialization of up to four T cell programs for hematologic malignancies and solid tumors.
Around 40% of Pfizer’s portfolio was realized through partnerships, and Monday, the pharma giant announced three more collaborative deals.
The planned acquisition will give Takeda full access to Adaptate’s antibody-based γδ T cell engager platform, which includes both pre-clinical and discovery assets.
Bayer and Mammoth Biosciences forged a strategic collaboration potentially valued at more than $1 billion. The partnership grants Bayer access to Mammoth’s CRISPR technology to develop in vivo gene-editing therapies.
BioSpace sat down with 12 executives who shared their thoughts on the coming year and decade.
Absci Corporation inked a deal with Merck. Absci will leverage its Bionic Protein non-standard amino acid technology and AI-integrated Drug Creation Platform to create enzymes for Merck.
Eli Lilly acquired rights to a technology from Entos Pharmaceuticals that boosts the development of nucleic acid therapeutics for the central and peripheral nervous system.
The acquisition is expected to bolster Odyssey’s drug development capabilities in immunology and oncology.
Three IPO aspirants have stepped up at the start of the new year: CinCor Pharma, Amylyx and Applied UV